Viatris agrees to buy Pacira: UBS lifts target for Viatris stock

Published on 10/18/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viatris agreed to buy Pacira for USD 1.65 billion on October 8, 2026. Q2 revenue reached USD 3.76 billion.

Pacira deal and analyst targets

Viatris agreed to acquire Pacira for USD 1.65 billion on October 8, 2026.
UBS raised its Viatris target from USD 23.00 to USD 26.00 on October 5, 2026.
Viatris stock last traded at USD 18.66 at 4:00 p.m. EDT on October 16, 2026.
Viatris will report third-quarter 2026 results on November 5, 2026.

Architekturvisualisierung eines generischen modernen Filmstudio-Backlot mit großen Hallenbauten — Paramount Global (US92556V1061) Architektur-Render zeigt modernen generischen Filmstudio-Backlot-Komplex im minimalistischen Baustil klar, Illustration mit AI erstellt.

Viatris Inc. (ISIN US92556V1061) agreed to acquire Pacira BioSciences for USD 1.65 billion on October 8, 2026, adding two marketed pain medicines to its branded portfolio. Viatris said the transaction is expected to close by the end of 2026 and should be immediately accretive to its financial guidance metrics.

Pacira adds branded medicines

The transaction values Pacira at USD 36.50 per share in cash and brings Exparel and Zilretta into Viatris. Pacira generated USD 746.0 million in revenue and USD 177.0 million in adjusted EBITDA during the twelve months ended June 30, 2026, according to the company release.

Reuters reported on October 8, 2026 that Viatris plans to fund the acquisition primarily with excess cash and short-term borrowings. The deal therefore shifts the company further toward higher-value branded medicines while preserving a large generics business.

What do the results show?

Viatris reported USD 3.76 billion in revenue and a GAAP net loss of USD 118.8 million for the second quarter of 2026. Revenue was USD 3.58 billion in the second quarter of 2025, while the prior-year GAAP net loss was USD 4.6 million, according to Markets Insider.

Analyst targets diverge

UBS raised its target from USD 23.00 to USD 26.00 on October 5, 2026 and kept a Buy rating, as reported by Markets Insider. Bank of America Securities maintained a Sell rating with a USD 16.00 target on October 12, 2026, while Piper Sandler maintained Hold with a USD 13.00 target.

Next reporting date

Viatris will report third-quarter 2026 financial results on November 5, 2026, at 8:30 a.m. ET, according to its October 5, 2026 release. That report will give investors the first scheduled read on the Pacira transaction's effect on guidance and leverage.

Stock stays tied to the deal

Viatris stock last traded at USD 18.66 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT. Its market capitalization was USD 21.4 billion and its 52-week range was USD 9.92 to USD 18.67 on that date. The further course of trading is shown by the continuously updated real-time quote of Viatris stock.